How to Evaluate Stability When the Biotech Market Is Anything but Stable

If you’ve been in biotech for any length of time, you already understand one thing.

Stability is never guaranteed.

A company can look strong from the outside. Good funding, promising science, a pipeline that makes sense, and a hiring push that suggests momentum. Everything lines up on paper.

Then something shifts.

Funding gets tighter. Priorities change. Leadership adjusts direction. What looked like a clear path forward starts to feel less certain.

That is not unusual in this space. It is part of how the market works.

So when you are evaluating a role, especially at the senior level, you cannot rely on what is visible on the surface. You have to understand what is actually holding the organization together underneath.

Because what you are really trying to figure out is not whether the company looks stable today.

You are trying to figure out whether it will hold up when things change.

The Surface-Level Signals Only Tell You So Much

Most people start in the same place when they evaluate a company.

They look at funding. They look at the pipeline. They look at where the company is in its lifecycle. Pre-revenue, early-stage, commercial, or somewhere in between.

That is all necessary. You need that context.

You need to understand what the company is trying to do, how far along they are, and whether they have the resources to get there. That is the baseline.

But it is only the beginning.

Because those signals do not tell you how the company actually operates. They tell you what is possible, not what is likely.

You can have strong funding and still have instability. You can have a compelling pipeline and still struggle internally. You can have a great story and still lack alignment.

The mistake is stopping at what is visible.

Real stability shows up in how the organization functions day to day.

It Starts With the Science, But It Does Not End There

In biotech, everything begins with the science.

If the science is not there, nothing else matters. You are not getting funding, you are not building a pipeline, and you are not moving forward. That is the starting point.

From there, funding becomes the next layer.

A company needs capital to operate. That part is obvious. What is less obvious is how that capital is structured and how it is used.

Not all funding creates stability.

A company can raise money and still create problems for itself depending on how that funding is set up. If the expectations tied to that capital are unrealistic, or if the company does not manage it well, it can create pressure instead of stability.

So when you look at funding, it is not just about how much they have raised. It is about how they are operating with it.

That brings you to leadership.

Leadership is where stability either starts to take shape or starts to break down.

You can have strong science and solid funding, but if leadership does not know how to navigate the situation, it does not hold. I have seen companies get funded and still struggle because they did not handle that position correctly.

They either misjudged where they were, misunderstood what needed to happen next, or failed to align the organization around a clear direction.

Strong leadership is not just about making decisions. It is about understanding how all the pieces fit together and what needs to happen at each stage.

And it does not stop with one person.

Leaders have to build out other leaders around them. They have to bring in people who can take ownership of different parts of the organization and move them forward.

If leadership is hesitant to do that, or if they do not build a strong team underneath them, the organization becomes fragile.

That fragility shows up later.

The Most Important Relationship Is the One You Report Into

There is one factor that carries more weight than most people give it.

The person you are reporting to.

At the end of the day, your experience in a role is going to be shaped heavily by that relationship. You are not just joining a company. You are working directly with a leader who has a specific way of thinking, a specific set of expectations, and a direction they are trying to take the organization.

You have to understand that.

You have to understand what they are trying to do and whether that aligns with what you want to do.

If it does not, the situation becomes difficult quickly.

It does not matter how strong the company looks. It does not matter how good the opportunity seems. If you and that person are not aligned, it is not going to work over time.

That is why the interview process is so important.

You are not just answering questions. You should be asking them.

Where are they taking the organization. What are they trying to build. How do they think about success. What do they expect from you in the role.

And you have to listen carefully to the answers.

Because this is where you start to see whether there is alignment or not.

A lot of people overlook this and focus on the company as a whole. But in reality, most people do not leave companies. They leave managers.

If that relationship is not right from the beginning, it usually does not get better.

Stability Shows Up in How Decisions Are Made

Another strong signal of stability is how decisions happen inside the organization.

Not just what decisions are made, but how they are made.

In a stable environment, there is clarity.

People understand what needs to be done and when. There is a sense of direction. Even if things change, there is an explanation behind it. There is a logic to how priorities shift.

You can follow it.

In a less stable environment, it feels different.

Decisions seem reactive. Priorities move without context. You hear different answers from different people. There is no consistent thread that ties everything together.

That lack of clarity creates problems.

Because if people do not understand what they are working toward, they cannot execute effectively. They spend time trying to interpret what is happening instead of focusing on the work itself.

You can usually pick up on this during the interview process.

Listen to how people describe the company.

Are they clear about what the organization is doing and why. Do their answers line up with each other. Do they explain how decisions are made, or do they speak in general terms that do not connect.

That tells you a lot.

Because decision-making is not something that changes overnight. It reflects how the organization is structured and how leadership operates.

Pay Attention to How Honest the Company Is

Not every company presents itself the same way.

Some will give you a very clean version of the story.

Everything is going well. The trajectory is strong. The opportunity is clear. There are no real issues to speak of.

That should raise a flag.

Because no company operates without challenges.

The more reliable signal comes from companies that are willing to show you the full picture.

They will tell you what is working, but they will also tell you what is not. They will talk about things that did not go as planned. They will explain where adjustments had to be made and why.

That level of transparency matters.

It shows that they understand their own situation. It shows that they are not trying to create a perfect narrative that does not match reality.

And it gives you a more accurate view of what you are stepping into.

The companies that oversell tend to run into issues later.

People join expecting one thing and experience something else. That gap creates frustration, and eventually, people leave.

When a company is upfront about both the strengths and the challenges, it reduces that gap.

You know what you are walking into.

Alignment Is What Actually Holds Things Together

When you step back and look at all of this, stability comes down to one thing.

Alignment.

Alignment between the science and the strategy. Alignment between how the company is funded and how it is operating. Alignment between leadership and the direction they are taking.

And alignment between you and the person you are reporting to.

If those things are in place, the organization can handle change.

Because change is going to happen.

Markets shift. Funding conditions change. Priorities evolve. That is normal in biotech.

What matters is whether the organization can adjust without breaking.

Alignment is what allows that to happen.

If leadership is aligned with the strategy, decisions make sense. If teams are aligned with leadership, execution follows. If expectations are clear, people know what they are responsible for.

Without alignment, even strong companies struggle.

Things start to pull in different directions. Decisions do not connect. People lose confidence in what they are working toward.

That is when stability breaks down.

Evaluating Whether a Role Will Hold Up

So when you are evaluating a role, you have to think beyond whether it looks good today.

You have to think about whether it will hold up.

Start with the basics. Understand the science. Understand the funding. Understand the stage of the company.

Then go deeper.

Look at leadership. How they think, how they operate, how they are building the organization. Pay attention to the person you will be working for and whether you are aligned with them.

Listen for clarity in how decisions are made. Watch for consistency in how people describe the company.

And be cautious of situations that feel too perfect.

Because in this market, nothing is perfect.

The Reality of Stability in Biotech

The reality is that stability in biotech is never absolute.

It is not something you either have or do not have.

It is something that depends on how well the organization is built to handle change.

Some companies are better positioned than others.

They have strong foundations. They have leadership that understands what they are doing. They have alignment across the organization. They make decisions in a way that people can follow.

Those companies are not immune to change, but they can navigate it.

Others look strong on the surface but do not have that same structure underneath.

When things shift, they struggle to adjust. That is when instability shows up.

The Bottom Line

If you are evaluating a role in biotech, you have to go past what is obvious.

Funding, pipeline, and growth narratives matter, but they are not enough on their own.

What matters is how the organization actually operates.

How leadership thinks. How decisions are made. How aligned the company is internally. And how well that aligns with you.

Because the question is not whether the role looks good today.

The question is whether it will still make sense when things change.

And if you know what to look for, you can answer that before you ever take the job.

 

About The Author:

Steve Swan works with senior technology leaders across biotech and pharma, helping companies build strong teams and helping individuals evaluate opportunities in a market that is constantly shifting. With decades of experience advising on hiring and organizational structure, he focuses on how companies actually operate beneath the surface, how leadership decisions play out over time, and what signals indicate whether a role or organization will hold up when conditions change.

 

Are you looking for top IT talent in the pharmaceutical or biotech industry?

Contact us to discuss how we can bring top-tier IT talent to your organization. The Swan Group are executive leaders with extensive IT recruiting expertise in the biotech and pharmaceutical space. Our goal is to ensure that each professional we place and each client we work with achieves a competitive advantage based upon our services.

Are you a professional looking for a new opportunity?

Contact us to discuss your career options or browse our opportunities. As a small boutique firm, we are in the business of building careers, not just filling positions.

ABOUT THE SWAN GROUP

Our goal is to ensure that each professional we place and each client we work with achieves a competitive advantage based upon our services. Our specialty is high-level INFORMATION TECHNOLOGY placement within the Pharmaceutical, Bio-Pharmaceutical, and Consumer Products industries. Thoughts, comments, or would like to discuss further, please contact us.